- Home
- netherlands antilles
- Equipment
Show results for
Refine by
Entero Medical Equipment & Supplies In Netherlands Antilles
5 equipment items found
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
Latiglutenase (IMGX003) is an orally administered mixture of two gluten-specific recombinant proteases that degrades gluten proteins into small physiologically irrelevant fragments that is designed to be administered as an adjunct to a gluten-free diet ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-UP is a niclosamide-based, oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS). FW-UP is currently being investigated in a Phase 2b clinical trial study to study the safety and potential efficacy of niclosamide in patients with UP and ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). Adrulipase is derived from the Yarrowia lipolytica yeast lipase and is designed to break up fat molecules in the digestive tract of EPI patients so that they can be ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
Capeserod is a selective 5-HT4 receptor partial agonist, which Entero Therapeutics is repurposing and developing for multiple GI conditions. Based on the biological evidence of expression of 5-HT4b receptor subtype in human GI tract, Entero Therapeutics believes that capeserod may directly or indirectly initiate the peristaltic or secretory reflex by releasing neurotransmitters that can decrease ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...